Showing posts with label Mass Medical Angels. Show all posts
Showing posts with label Mass Medical Angels. Show all posts

Wednesday, June 19, 2013

Angels Syndicate Deals in ZetrOZ and Groupize for $4.5M and $2M; Launchpad in Both; Groupize Quickly Oversubscribed.



ZetrOZ of Trumbull, CT has just completed a   syndicated A-round financing of $4.5M.   Funds came from Connecticut Innovations, Mass Medical Angels, Boston Harbor Angels, Launchpad Venture Group, and other individual Angels.  “Connecticut Innovations is the lead investor for the entire A Round, although Mass Medical Angels played a significant role leading the Boston based investors,” according to CEO Bryant Guffey.   As a result of this financing round, ZetrOZ, Inc relocated to Connecticut from Ithaca, NY.  Connecticut Innovations is the preferred shareholder with a board seat, followed by 2 independent directors and 2 common shareholder directors. Mass Medical Angels and Launchpad Venture Group both have observation rights.

“We are very excited and proud to have gained the support of top Angel and Venture groups in the Northeastern Region,” says Guffey. “Upon relocating to Connecticut in January 2013 we gained significant access to both financial and personnel resources in CT, MA, and NY.  Support from our new investors has expanded our ability to scale quickly in preparation for product launch later this year.  Frankly, I’ve been impressed by the Boston and Connecticut based investment communities in both their professional process and willingness to move quickly to seize the opportunity!”

 ZetrOZ is an innovative ultrasound technology company focused on developing a new generation of ultrasound products and applications. Utilizing its powerful, proprietary “OZ Inside™” miniaturization technology, ZetrOZ can deliver the spectrum of ultrasound more efficiently, more economically, and more compactly than ever before. The company spun off of from Cornell with technology in ultrasound miniaturization that cofounder Dr. George Lewis invented during his PhD research in biomedical engineering.

Groupize.  Launchpad and Golden Seeds member Sheryl Schultz first spotted the company at a pitch contest. The fundraising goal of $2M was quickly oversubscribed. Golden Seeds led the deal, joined by Launchpad. The Golden Seeds fund also invested.  The company was invited to pitch to the Maine Angels this month, but closed this round beforehand. “Looks like it generated a lot of interest!” says Sandra Stone of the Maine Angels. We hear Sidecar Angels was also interested.

Groupize, of Gloucester, MA,   provides a SaaS platform for allowing Hotel chains and big travel players like Expedia to deal with the perennial issue of booking small groups.  Booking singles is automated and booking huge groups is manual and cost effective that way.  Booking small groups has been a disaster - too expensive to do manually, too complex to automate.  Groupize has built a platform that allows chains and big guys to expose inventory, quote small groups, book small groups and generally solve the pain.  They have Wyndam, a couple million in revenue, and are closing in on one of the major internet travel sites.

We congratulate Launchpad in particular for playing a role in both of these syndicates.  Voices we have heard on high tell us that Launchpad invested close to $2M in these two companies, most likely moving Launchpad once again into  record setting results  in Q2


We appear to be the only publication covering angel syndicates as such. Syndications we have reported on recently include:

Tuesday, June 11, 2013

Northeast Based Angel Syndicate Heads West to Lead an $11.4M B Round for Avaxia Biologics of Lexington, MA.



Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company closed its Series B financing with total proceeds of $11.4 million. The round was led by Cherrystone Angels and Golden Seeds.

Previous investors Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, North Country Angels, the Beta Fund, Granite State Angels, the Keiretsu Forum, Maine Angels, and individual investors, all participated in the round. They were joined by Ariel Southeast Angel Partners, and Tech Coast Angels.   AbbVie Biotech Ventures—the VC arm of the multi-billion dollar pharmaceutical business spun out by Abbott Laboratories in January—has become Avaxia’s first institutional investor and joined the group.

“I have been building relationships with the angel community for many years – talking to and presenting to New England life sciences angel groups for over 5 years,” says Avaxia CEO Barbara Fox. “Our Series A financing was composed entirely of New England angel groups, and we branched out to a national syndicate for the Series B. Our board and existing angel base was instrumental in facilitating those discussions.”

Avaxia has now raised $15.5 million in equity and about $6 million in non-dilutive grants and contracts since its inception, Fox says.

This is the second very large angel syndication announced this year. Recently, Savara Pharmaceuticals’, based in Austin, Texas, raised $16 million in a round led by the Tech Coast Angels. Three other angel networks -- Keiretsu Forum, the Central Texas Angel Network and the North Texas Angel Network – also participated.  “Completing a Series B of this size with 100 percent angel money is a major accomplishment,” said Sergio Gurrieri, who helped orchestrate Tech Coast Angels evaluation of Savara. “It demonstrates Tech Coast Angels’ increasing effectiveness at syndicating deals with other angel networks to raise larger rounds and drive innovation.”

At that time we wrote “Here in New England, we’ve managed a  $2 Million syndication, but we’ll have to reach higher to follow the example of our colleagues out West.”  We just reached higher.  Particular congratulations to the Tech Coast Angels and the Keiretsu Forum for participating in both of these very large financings,  demonstrating once again the emerging power of angel syndication.

Avaxia will primarily use the proceeds of this round to advance the clinical development of its lead program, AVX-470, for the treatment of inflammatory bowel disease (IBD).

The Series B financing represents an important milestone for Avaxia in the process of developing a safe, effective, oral therapy for patients suffering from IBD. We're pleased to have David Donabedian  of AbbVie join our board and engage their expertise in gastroenterology as we advance the development of innovative, gut-targeted therapeutics like AVX-470, said Barbara S. Fox, CEO of Avaxia.